eligibility_summary
Eligible: histologically confirmed lymphoid neoplasm lacking standard options—R/R cHL (≥3 prior incl ASCT or PD‑1, or ≥2 if no options), R/R PTCL (≥2, or ≥1 if no options), R/R sALCL (≥2 incl a brentuximab regimen, or ≥1 BV+CHP), R/R DLBCL (≥2 incl ASCT and CAR‑T, or ineligible/refused). Parts A/B: PTCL/DLBCL need CD30≥1%, Part C: any CD30, tissue required. ECOG≤1, FDG‑PET‑avid measurable disease. Exclude: prior camptothecin‑ADC, malignancy <3y, active CNS, ASCT <12w, allo‑SCT <100d/immunosuppression/GVHD, major GI bleed/obstruction/perf <6m.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
PF-08046044/SGN-35C is an intravenous antibody-drug conjugate (ADC) targeting CD30. After binding CD30 on malignant lymphocytes, it is internalized and releases a camptothecin-based topoisomerase I inhibitor payload, inhibiting Topo I, disrupting DNA replication, and inducing DNA damage/apoptosis. First-in-human, phase 1 monotherapy with dose escalation/optimization/expansion in adults with advanced lymphomas: classical Hodgkin lymphoma, peripheral T-cell lymphoma (including systemic ALCL), and DLBCL (with CD30 expression in early parts). Targets: CD30+ tumor cells and the Topo I/DNA replication pathway.